tiprankstipranks
PMV Pharmaceuticals reports FY22 EPS ($1.61), consensus ($1.64)
The Fly

PMV Pharmaceuticals reports FY22 EPS ($1.61), consensus ($1.64)

"Our team successfully delivered on key clinical development milestones in 2022, highlighted by the preliminary monotherapy data from the ongoing PYNNACLE study, and the initiation of a separate combination arm of PC14586 with KEYTRUDA," said David Mack, Ph.D., President and Chief Executive Officer. "The initial PC14586 data have demonstrated clinical proof of concept for PC14586 as a monotherapy to selectively reactivate p53 across multiple tumor types. In alignment with FDA draft guidance on Project Optimus, we continue to enroll additional patients in the PYNNACLE study and intend to provide a comprehensive clinical and regulatory update, including our recommended Phase 2 dose, in the second half of 2023."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PMVP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles